Summary
- Current Price
- As of today, INCY price is $121.55, up +0.82% on
- Current Price All-Time High
- INCY price is currently -20.63% below its historical high of $153.15 set on
- Market Cap
- INCY current market cap is $25B, up +61.91% over the past 365 days
- PE Ratio
- INCY current PE ratio is 15.49
- Revenue
- INCY current annual revenue is $5.14B, up +21.22% year-over-year
- Next Earnings
- The next earnings release for INCY is on
Profile
| Metric | Value |
|---|---|
| Full Name | Incyte Corporation |
| Ticker | NASDAQ: INCY |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | |
| Website | incyte.com |
| Employees | 2,617 |
Key Metrics
| Metric | Value | Date |
|---|---|---|
| Price | $121.55 | |
| Price, 1D Change | +0.82% | |
| Market Cap | $25B | |
| - | ||
| PE Ratio | 15.49 | |
| Beta | 0.43 | |
| Revenue | $5.14B | |
| Revenue, 1Y Change | +21.22% | |
| EPS | $6.41 | |
| EPS, 1Y Change | +4,038.67% |
Chart
SUGGESTED SERIES
Events
| Metric | Value | Date |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | 2:1 | |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Value | Date |
|---|---|---|
| EPS | $6.41 | |
| EPS Estimate | $3.56 | N/A |
| EPS Est. Change | -44.54% | N/A |
| Revenue | $5.14B | |
| Revenue Estimate | $5.94B | N/A |
| Revenue Est. Change | +15.59% | N/A |
| Current Price | $121.55 | |
| Price Target | $120.00 | - |
| Price Tgt. Change | -1.28% | - |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $1.29 | $0.15 | -88.01% | |
| $6.89 | $6.41 | -6.97% | |
| $3.56 | N/A | -44.54% | |
| $8.88 | N/A | +38.54% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $4.20B | $4.24B | +1.05% | |
| $4.98B | $5.14B | +3.24% | |
| $5.94B | N/A | +15.59% | |
| $6.26B | N/A | +21.67% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Value | Date |
|---|---|---|
| Price, 1Y | +55.06% | |
| Price, 3Y | +85.54% | |
| Market Cap, 1Y | +61.91% | |
| Market Cap, 3Y | +68.40% | |
| Revenue, 1Y | +21.22% | |
| Revenue, 3Y | +51.45% | |
| EPS, 1Y | +4,038.67% | |
| EPS, 3Y | +321.46% |
🔒 Log In To Unlock Full Data
Technicals
| Metric | Value | Date |
|---|---|---|
| Current Price | $121.55 | |
| SMA 200 | $102.24 | |
| SMA 50 | $111.85 | |
| EMA 200 | $100.84 | |
| EMA 50 | $113.31 | |
| MACD | $2.38 | |
| Beta | 0.43 | |
| ATR | $4.08 | |
| 14-Day RSI | 57.31 | |
| 10-Day Volatility | 57.71% |
Dividends
| Metric | Value | Date |
|---|---|---|
| - | N/A | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| $0.00 | ||
| 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Value | Date |
|---|---|---|
| Revenue | $5.14B | |
| EPS | $6.41 | |
| Gross Profit | $4.79B | |
| Gross Margin | 93.18% | |
| Operating Income | $1.34B | |
| Operating Margin | 26.12% | |
| Net Income | $1.29B | |
| Net Margin | 25.03% | |
| EBITDA | $1.44B |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Value | Date |
|---|---|---|
| Debt To Equity | 0.01 | |
| 3.29 | ||
| 3.02 | ||
| - | ||
| 7 | ||
| 10.26 |
Valuations
| Metric | Value | Date |
|---|---|---|
| PE Ratio | 15.49 | |
| 4.23 | ||
| 3.88 | ||
| 10.39 | ||
| - | N/A |
Balance Sheet
| Metric | Value | Date |
|---|---|---|
| Book Value | $5.17B | |
| $3.58B | ||
| $6.97B | ||
| $5.39B | ||
| $1.80B | ||
| $1.63B | ||
| Total Debt | $34.72M | |
| $10.21M | ||
| $1.63B |
Expenses
| Metric | Value | Date |
|---|---|---|
| $3.85B | ||
| $3.45B | ||
| $438.72M | ||
| $0.00 | ||
| $93.29M | ||
| $0.00 | ||
| $377.80M |
Cash Flow
| Metric | Value | Date |
|---|---|---|
| $1.41B | ||
| -$102.61M | ||
| $101.04M | ||
| Capex | $83.87M | |
| $1.33B |
Recent analyst updates
| Metric | Value | Date |
|---|---|---|
| Mizuho | → | |
| Leerink Partners | → | |
| HC Wainwright & Co. | → | |
| RBC Capital | → | |
| HC Wainwright & Co. | → | |
| Guggenheim | → | |
| BMO Capital | → | |
| Barclays | → | |
| Morgan Stanley | → | |
| JP Morgan | → |
Analyst sentiment
Institutional ownership
No data
Screeners with INCY
FAQ
- What is the ticker symbol for Incyte Corporation?
- The ticker symbol for Incyte Corporation is NASDAQ:INCY
- Does Incyte Corporation pay dividends?
- No, Incyte Corporation does not pay dividends
- What sector is Incyte Corporation in?
- Incyte Corporation is in the Healthcare sector
- What industry is Incyte Corporation in?
- Incyte Corporation is in the Biotechnology industry
- What country is Incyte Corporation based in?
- Incyte Corporation is headquartered in United States
- When did Incyte Corporation go public?
- Incyte Corporation initial public offering (IPO) was on November 4, 1993
- Is Incyte Corporation in the S&P 500?
- Yes, Incyte Corporation is included in the S&P 500 index
- Is Incyte Corporation in the NASDAQ 100?
- No, Incyte Corporation is not included in the NASDAQ 100 index
- Is Incyte Corporation in the Dow Jones?
- No, Incyte Corporation is not included in the Dow Jones index
- When was Incyte Corporation last earnings report?
- Incyte Corporation's most recent earnings report was on July 28, 2026
- When does Incyte Corporation report earnings?
- The next expected earnings date for Incyte Corporation is October 27, 2026
Data Sources & References
- INCY Official Website www.incyte.com
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/879169/000087916926000010/0000879169-26-000010-index.htm
- List of S&P 500 Companies www.spglobal.com/spdji/en/indices/equity/sp-500/#overview
- INCY Profile on Yahoo Finance finance.yahoo.com/quote/INCY
- INCY Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/incy
